Abstract: The present invention relates to the field of boron-containing compounds, particularly boron compounds and pharmaceutical compositions thereof that exhibit with antibacterial and/or anti-inflammatory activities, and uses thereof. Methods for preparing and using these boron compounds and pharmaceutical compositions thereof, are also provided.

Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.

Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.

Abstract: This invention is directed generally to a process for making ?-substituted hydroxamic acids (including salts thereof) generally corresponding in structure to Formula (I): wherein n, Z, Z3, A, R, E, and Y are as defined in this patent. This invention also is directed to compounds that may, for example, be used as intermediates in such a process, as well as processes for making such compounds.

Abstract: This invention relates to improved polypropylene nonwoven fabrics. The fabrics are made from isotactic polypropylene which has been produced with a catalyst systems comprising at least two metallocenes. These nonwoven fabrics, particularly when prepared using a spunbonding process, exhibit significantly improved strength without significant sacrifice of other favorable properties.

Abstract: A propylene, .alpha.-olefin copolymer, where the .alpha.-olefin has 5 or more carbon atoms made with a metallocene catalyst system provides substantially higher cold flow resistance from when the propylene copolymer is made with an .alpha.-olefin having 4 or less carbon atoms. Other properties such as ultimate tensile strength and impact strength are substantially higher as well. Such polymers can be used to advantage in fibers, fabrics, and oriented films.